We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current PTGX market cap is 1.52B. The company's latest EPS is USD -1.3549 and P/E is -19.25.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -32.3M | -36.52M | -36.02M | -42.35M | -38.33M |
| Net Income | -31.23M | -34.19M | -33.73M | -38.46M | -34.11M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 231k | 28.63M | 27.36M | 26.58M | 60M |
| Operating Income | -80.52M | -64.52M | -125.85M | -131.37M | -93.65M |
| Net Income | -77.19M | -66.15M | -125.55M | -127.39M | -78.96M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 282.17M | 247.93M | 239.86M | 320.47M | 330.02M |
| Total Liabilities | 38.56M | 32.32M | 23.69M | 26.4M | 27.87M |
| Total Equity | 243.62M | 215.61M | 216.17M | 294.07M | 302.15M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 154.92M | 324.47M | 347.7M | 247.93M | 357.95M |
| Total Liabilities | 74.95M | 44.86M | 47.67M | 32.32M | 21.27M |
| Total Equity | 79.96M | 279.61M | 300.02M | 215.61M | 336.68M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -76.5M | -108.14M | -34.35M | -60.59M | -87.2M |
| Investing | 87.53M | 91.47M | 9.83M | 35.59M | 22.03M |
| Financing | 18.29M | 18.84M | 26.46M | 134.64M | 169.95M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -41.53M | -72.48M | -107.87M | -108.14M | -70.24M |
| Investing | -53.71M | -90.97M | -15.86M | 91.47M | -39.26M |
| Financing | 46.04M | 247.63M | 129.92M | 18.84M | 170.48M |
| Market Cap | 1.52B |
| Price to Earnings Ratio | -19.25 |
| Price to Sales Ratio | 25.33 |
| Price to Cash Ratio | 8.14 |
| Price to Book Ratio | 4.51 |
| Dividend Yield | - |
| Shares Outstanding | 58.27M |
| Average Volume (1 week) | 562.11k |
| Average Volume (1 Month) | 509.09k |
| 52 Week Change | 9.99% |
| 52 Week High | 33.34 |
| 52 Week Low | 13.72 |
| Spread (Intraday) | 3.61 (13.07%) |
| Company Name | Protagonist Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.protagonist-inc.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
